Clinical Trial Detail

NCT ID NCT03562637
Title Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors OBI Pharma, Inc
Indications

triple-receptor negative breast cancer

Therapies

Adagloxad simolenin + OBI-821

Age Groups: senior adult

No variant requirements are available.